VistaGen Therapeutics Announces Appointment of Mary L. Rotunno to its Board of Directors Ms. Rotunno brings extensive healthcare industry expertise as a leader and strategist as VistaGen advances late-stage development o

VistaGen Therapeutics Announces Appointment of Mary L. Rotunno to

its Board of Directors

Ms. Rotunno brings extensive healthcare industry expertise as a

leader and strategist as VistaGen advances late-stage development

of its product candidates for anxiety and depression

SOUTH SAN FRANCISCO, Calif.

VistaGen Therapeutics,

biopharmaceutical company committed to developing a new generation

of medicines with the potential to go beyond the current standard

of care for anxiety, depression and other central nervous system

( CNS ) disorders, today announced the appointment of

Mary L. Rotunno, J.D. to its Board of Directors

brings to our team more than 30 years of leadership experience,

which began with serving patients as a registered nurse and

transitioned to serving clients in health care law, both allowing

her to pursue her steadfast commitment to helping others and

advancing the future of mental health and wellness, said Shawn Singh,

Chief Executive Officer of VistaGen. Her extensive track

record as an advocate for both patients and health care providers

is unique and will provide deep and valuable insights into

strategies for value-based care and an

understanding of the entire life cycle of the mental healthcare

experience. Mary has also served as a trusted advisor on complex

governance, regulatory and compliance requirements for several

companies. Her strategic vision, skill for scenario planning, and

enterprise risk management expertise will be key in the next phases

of our corporate development as we continue to pursue our core

mission - to improve mental health and well-being for individuals

in the U.S. and abroad.

Rotunno is currently General Counsel and Member of the Executive

Leadership Team at El Camino Health, a $1 billion revenue health

is also Board Chair and a member of Audit, Executive/Governance and

Nominations Committees for health care provider, Momentum for

Health, in Silicon Valley. Before joining El

Camino Health in early 2014, Ms. Rotunno spent over 11 years

as Senior Counsel and Client Service Leader for Common Spirit

Health, formerly Dignity Health, in San Francisco Bay Area.

Prior to Dignity Health, she held various legal roles at Varian

Medical Systems, Manatt, Phelps & Phillips, Golden Living, and

Pillsbury Winthrop Shaw Pitman. She graduated with honors from the

University of Illinois with a Bachelor of Science in Nursing. She

worked as a registered nurse before earning her Juris Doctor

degree, cum laude, from the University of California, Hastings

College of Law, San Francisco. She obtained

certification by the Women's Corporate Board Readiness

Program at Santa Clara University and completed the Hastings

Leadership Academy for Women and Dignity Health Ministry Leadership

VistaGen Therapeutics is a biopharmaceutical company committed to

developing and commercializing innovative medicines with the

potential to go beyond the current standard of care for anxiety,

depression, and other CNS disorders. Each of VistaGen's three drug

candidates has a differentiated potential mechanism of action, has

been well-tolerated in all clinical studies to

potential in multiple CNS markets. For more information, please

visit www.VistaGen.com

and connect with VistaGen

Forward Looking Statements

press release contains certain forward-looking statements within

the meaning of the federal securities laws. These forward-looking

statements involve known and unknown risks that are difficult to

predict and include all matters that are not historical facts. In

some cases, you can identify forward-looking statements by the use

of words such as may, could,

expect, project, outlook,

strategy, intend, plan,

strive, goal, continue,

likely, will, would and

variations of these terms and similar expressions, or the negative

of these terms or similar expressions. Such forward-looking

statements are necessarily based upon estimates and assumptions

that, while considered reasonable by us and our management, are

inherently uncertain. Our actual results or developments may differ

materially from those projected or implied in these forward-looking

statements. Factors that may cause such a difference are fully

discussed in the section entitled "Risk Factors" in our most recent

Annual Report on Form 10-K for the fiscal year ended March 31,

2021, as well as discussions of potential risks, uncertainties, and

other important factors in our other filings with the U.S.

Securities and Exchange Commission (SEC). Our SEC filings are

available on the SEC's website at www.sec.gov. You should not

place undue reliance on these forward-looking statements, which

apply only as of the date of this press release and should not be

relied upon as representing our views as of any subsequent date. We

explicitly disclaim any obligation to update any forward-looking

statements, other than as may be required by law. If we do update

one or more forward-looking statements, no inference should be made

that we will make additional updates with respect to those or other

forward-looking statements.

VistaGen Company Contacts

McPartland / Mark Flather

VistaGen Therapeutics

Email: IR@vistagen.com